(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 15.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Newamsterdam Pharma Co Nv's revenue in 2025 is $74,425,581.On average, 14 Wall Street analysts forecast NAMS's revenue for 2025 to be $3,421,652,554, with the lowest NAMS revenue forecast at $2,439,307,143, and the highest NAMS revenue forecast at $5,570,040,390. On average, 13 Wall Street analysts forecast NAMS's revenue for 2026 to be $1,535,463,768, with the lowest NAMS revenue forecast at $0, and the highest NAMS revenue forecast at $7,947,063,996.
In 2027, NAMS is forecast to generate $16,167,815,146 in revenue, with the lowest revenue forecast at $2,580,543,230 and the highest revenue forecast at $38,010,978,290.